Skip to search formSkip to main contentSkip to account menu

EBI-005

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase 3 Multi-Center Trial Evaluating the Efficacy, Safety and Tolerability of Isunakinra (EBI-005) in Subjects with Moderate to Severe Allergic Conjunctivitis
Presentation #2307 /Poster #C0121, ARVO Annual Meeting, Session #: 113, Session Title: Allergic conjunctivitis / Corneal… 
2016
2016
A Multi-Center Phase 3 Safety and Tolerability Study of Isunakinra (EBI-005) in Subjects with Moderate to Severe Dry Eye Disease
2015
2015
Clinical Development of EBI-005, a Novel Interleukin-1 Receptor Inhibitor, for Patients with Ocular Surface Inflammation
Presentation #4488/Poster #A0114, ARVO Annual Meeting, Session #: 438, Session Title: Dry eye disease, II, Wednesday, May 6, 2015… 
2015
2015
Novel Therapy for Allergic Conjunctivitis Patients Using Ebi-005, a Topical Intereukin-1 Receptor Inhibitor
2014
2014
IL-1 blockade for the topical treatment of ocular surface inflammatory disorders and the discovery of EBI-005, a novel IL-1 receptor inhibitor
There remains a substantial unmet medical need in the treatment of ocular surface inflammatory disorders, such as moderate to… 
2013
2013
Preclinical Development of EBI-005: a Potent Interleukin-1 (IL-1) Receptor-1 (R1) Blocker for Topical Ocular Administration was Safe in GLP Toxicology Studies and Active in a Mouse Model of Dry Eye…
1 Eleven Biotherpeutics, Cambridge, MA, United States. 2 Ophthalmology, Duke University School of Medicine, Durham, NC, United… 
2013
2013
Early Clinical Development of EBI-005, a Potent Interleukin-1 (IL-1) Receptor-1 (R1) Blocker for Topical Ocular Treatment of Dry Eye Disease (DED)
2012
2012
EBI-005: an Interleukin-1 Receptor Inhibitor Designed for the Treatment of Dry Eye Syndrome
Dry eye syndrome (DES) is an ocular surface inflammatory condition induced by desiccating stress and mediated by IL-1 stimulation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)